EXEL

Exelixis, Inc. (EXEL) - Q1 2002 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2002. Exelixis, Inc. is a biotechnology company focused on developing proprietary human therapeutics, primarily in cancer, using comparative genomics and model system genetics. The company operates through a mix of internal research and strategic collaborations with major pharmaceutical and agrochemical firms.

Key Financial Metrics

Note: Cash and short-term investments combined for Q1 2002 ($21,444 + $176,638) equals $198,082. Q1 2001 combined cash/investments derived from balance sheet data ($39,228 cash + $172,442 investments implied from prior period context, though Q1 2001 balance sheet not fully detailed in text, Q1 2001 cash flow end balance was $39,228).

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 50% to $11.6 million, driven by new collaborations with Protein Design Labs and Bristol-Myers Squibb, and compound deliveries.
• Expense Surge: Operating expenses rose to $31.5 million from $22.1 million. Research and Development (R&D) expenses jumped 57% to $26.4 million due to increased personnel costs (up 61%), lab supplies (up 105%), and licensing fees.
• Accounting Changes: The company adopted SFAS No. 142 on January 1, 2002, discontinuing the amortization of goodwill. This reduced amortization expense from $1.05 million in Q1 2001 to $0.17 million in Q1 2002.
• Cash Flow Deterioration: Net cash used in operating activities increased significantly to $26.3 million, compared to $0.6 million in the prior year, primarily due to funding net operating losses and payments related to the Genomica acquisition exit plan.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes current cash, investments, and collaborator funding are sufficient for at least the next two years. However, the company expects to continue incurring net losses and negative operating cash flow.
• Future Capital Needs: The company anticipates needing additional capital in the future to fund R&D, clinical trials, and manufacturing. It may seek public or private financing, which could be dilutive.
• Key Programs: The company is advancing a Rebeccamycin analogue (acquired from Bristol-Myers Squibb) currently in Phase II trials. It plans to file its first Investigational New Drug (IND) application for a proprietary compound in 2002.
• Risk Factors: Significant risks include the failure of clinical trials, inability to secure regulatory approval, dependence on collaborators for revenue and product development, and the potential for goodwill impairment. The company also faces risks related to the integration of acquisitions (Genomica, Artemis) and the sale of the Genomica software business (subsequent event).
• Subsequent Event: In April 2002, Exelixis sold the Genomica software business to Visualize Inc. for up to $2.35 million in future fees, expecting to record this as discontinued operations in Q2 2002.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $26.3 million quarterly operating cash burn against the $198 million cash/investment balance.
• Collaboration Revenue: Confirm the status and renewal terms of key agreements with Bristol-Myers Squibb, Bayer, and Aventis, which drive the majority of revenue.
• Clinical Progress: Monitor the timeline and results of the Phase II trials for the Rebeccamycin analogue and the filing of the first proprietary IND.
• Goodwill Valuation: Assess the $68.3 million goodwill balance for potential future impairment charges, especially given the company's history of losses.
• Genomica Exit: Review the final financial impact of the Genomica exit plan and the subsequent sale of its software business.